NCT00972842View on ClinicalTrials.gov

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Peripheral T-Cell Non-Hodgkin's Lymphoma
Interventions
DRUG

Vorinostat, Lenalidomide

"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"

Trial Locations (5)

A-6020

Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck

A-4010

Krankenhaus der Elisabethinen Linz, Linz

A-4020

Krankenhaus der Stadt Linz, Linz

A-5020

Universitaetsklinik f. Innere Medizin III, Salzburg

A-1140

Hanusch Krankenhaus, Vienna

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT00972842 - Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter